Psychopharmacological Neuroprotection in Neurodegenerative Disease: Assessing the

[1]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[2]  C. Clarke.  Are delayed‐start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? , 2008, Movement disorders : official journal of the Movement Disorder Society.

[3]  G. Ford.  Clinical pharmacological issues in the development of acute stroke therapies , 2008, British journal of pharmacology.

[4]  H. Mitsumoto,et al.  Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.

[5]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[6]  Sten Orrenius,et al.  Mitochondrial oxidative stress: implications for cell death. , 2007, Annual review of pharmacology and toxicology.

[7]  Y. Gupta,et al.  P52 EFFECT OF ADD-ON MELATONIN THERAPY ON ANTIOXIDANT ENZYMES IN EPILEPTIC CHILDREN ON VALPROATE MONOTHERAPY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL , 2006 .

[8]  N. Hardingham,et al.  Preconditioning Doses of NMDA Promote Neuroprotection by Enhancing Neuronal Excitability , 2006, The Journal of Neuroscience.

[9]  R. Kim.  Unknotting the roles of Bcl-2 and Bcl-xL in cell death. , 2005, Biochemical and biophysical research communications.

[10]  M. Feany,et al.  New genetic insights into Parkinson's disease. , 2004, The New England journal of medicine.

[11]  Y. Gupta,et al.  A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes. , 2004, British journal of clinical pharmacology.

[12]  Nicola Pavese,et al.  A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  R. Mani.  The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint , 2004, Statistics in medicine.

[14]  Yingpei Zhang,et al.  Caspases, apoptosis and aging , 2003, Ageing Research Reviews.

[15]  James Lowe,et al.  Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders , 2003, Ageing Research Reviews.

[16]  R. Albin,et al.  Neuroprotective agents for clinical trials in Parkinson’s disease , 2003, Neurology.

[17]  Robert M Friedlander,et al.  Apoptosis and caspases in neurodegenerative diseases. , 2003, The New England journal of medicine.

[18]  M. Gingold,et al.  CME Practice parameter : Evaluation of the child with global developmental delay , 2003 .

[19]  V. Rangnekar,et al.  Apoptosis by Par-4 in cancer and neurodegenerative diseases. , 2003, Experimental cell research.

[20]  P. K. Morrish,et al.  A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study , 2002, Journal of Neural Transmission.

[21]  David J Gladstone,et al.  Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions , 2002, Stroke.

[22]  R. Swerdlow.  Mitochondrial DNA--related mitochondrial dysfunction in neurodegenerative diseases. , 2002, Archives of pathology & laboratory medicine.

[23]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[24]  D. Knopman,et al.  Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. , 2001, The American journal of managed care.

[25]  D. Mohr,et al.  Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. , 2001, Archives of neurology.

[26]  Ming Xu,et al.  DNA fragmentation in apoptosis , 2000, Cell Research.

[27]  Stroke Therapy Academic Industry Roundtable.  Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.

[28]  D. Brenner,et al.  Confocal microscopy of the mitochondrial permeability transition in necrotic and apoptotic cell death. , 1999, Biochemical Society symposium.

[29]  A. Privat,et al.  Sigma1 (σ 1) receptor agonists and neurosteroids attenuate β 25–35-amyloid peptide-induced amnesia in mice through a common mechanism , 1998, Neuroscience.

[30]  R. Weichselbaum,et al.  Determination of cell fate by c-Abl activation in the response to DNA damage , 1998, Oncogene.

[31]  G. Schumock,et al.  Economic Considerations in Alzheimer's Disease , 1998, Pharmacotherapy.

[32]  C. Brenner,et al.  The modulation of inter-organelle cross-talk to control apoptosis. , 2006, Medicinal chemistry (Shariqah (United Arab Emirates)).